Medipure Holdings Inc.
CNSX : MDH

Medipure Holdings Inc.

November 13, 2014 08:00 ET

Medipure Holdings Announces Equity Offering

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 13, 2014) -

THIS PRESS RELEASE IS NOT INTENDED FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES, AND SHOULD NOT BE DISSEMINATED WITHIN THE U.S.

Medipure Holdings Inc. ("Medipure," or the "Company") (CSE:MDH) is pleased to announce that it intends to complete an equity offering for up to 1,375,000 of the Company's common shares at a price of $0.80 per share for total gross proceeds of up to $1,100,000 (the "Offering"). This Offering is subject to receipt of all applicable regulatory approvals.

Medipure intends to use the proceeds from this Offering to advance its goal of conducting pioneering research into the development of cannabinoid-based medicines as prescription pharmaceuticals. The majority of the proceeds will be utilized to complete the purchase of property for the Company's full-service production and research facility in Maple Ridge, British Columbia, and subsequently perform construction, engineering, and development work necessary to advance this facility towards completion. Proceeds will also be allocated towards the Company's operations, including product research and development.

All securities issuable under this Offering will be subject to a hold period of four months and one day from the date on which these securities are issued.

In connection with this Offering, Medipure will pay a finder's fee to arm's length parties of up to: (i) a maximum of 8% cash; and (ii) the issuance of warrants equal to 8% of the number of common shares sold to purchasers introduced by finders, with each warrant granting the right to purchase a common share at a price of $0.80 per share for a period of one year.

An Offering Memorandum describing this Offering in greater detail has been filed with SEDAR, and is available for viewing at www.sedar.com.

About Medipure Holdings Inc.

Medipure is developing an extensive network of strategic partnerships with extensive experience in developing cannabinoids, medicines containing controlled substances, as well as plant-based prescription pharmaceutical products. Medipure will attempt to bring novel prescription medicines to market, providing patients with serious conditions valuable solutions that make a real difference to quality of life. Medipure will also seek to maximize the value of our products through rapid cost- effective product development, addressing market needs, and establishing strategic partnerships. Although Medipure has applied to Health Canada for a license to produce and distribute medical marijuana under the Marihuana for Medical Purposes Regulations, it has not yet received such a license and there is no guarantee that such a license will be granted to Medipure by Health Canada.

Forward-Looking Statements

Information in this press release that is not current or historical factual information may constitute forward-looking information, including future-oriented financial information and financial outlooks, within the meaning of securities laws. This information is based on certain assumptions regarding expected growth, results of operations, performance, and business prospects and opportunities. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the companies cannot provide any assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release and the companies disclaim any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

This news release shall not constitute an offer to sell or the solicitation of any offer to buy the securities in any jurisdiction. The securities offered have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except in certain transactions exempt from the registration requirements of the U.S. Securities Act.

Contact Information